PMID- 18387510
OWN - NLM
STAT- MEDLINE
DCOM- 20080722
LR  - 20220321
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 8
IP  - 5
DP  - 2008 May
TI  - Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on 
      release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.
PG  - 679-87
LID - 10.1016/j.intimp.2008.01.013 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a vital component of the inflammatory 
      process and its aberrant over-expression has been linked to numerous disease 
      states. New treatment strategies have sought to reduce circulating TNF-alpha, 
      either with neutralizing anti-TNF-alpha binding proteins such as etanercept or 
      via drugs that inhibit de novo TNF-alpha synthesis like pirfenidone. In the 
      present study, we examined the effects of both classes of drugs on secreted and 
      cell-associated TNF-alpha produced by THP-1 cells. All of the tested drugs 
      significantly reduced secreted levels of bioactive TNF-alpha following 
      stimulation with LPS as measured by bioassay. However, etanercept-treated cells 
      had approximately six-fold higher levels of cell-associated TNF-alpha compared 
      with that of the LPS-alone treatment group. Surprisingly, LPS+infliximab treated 
      cells did not increase cell-associated TNF-alpha relative to the LPS-alone 
      treatment. Pirfenidone significantly reduced both secreted and cell-associated 
      TNF-alpha levels. These drug-related differences in cell-associated TNF-alpha may 
      have broad implications in the future for the therapeutic uses of anti-TNF-alpha 
      drugs in the management of TNF-alpha diseases.
FAU - Grattendick, K J
AU  - Grattendick KJ
AD  - Solanan, Inc., Dallas, TX 75229, USA.
FAU - Nakashima, J M
AU  - Nakashima JM
FAU - Feng, L
AU  - Feng L
FAU - Giri, S N
AU  - Giri SN
FAU - Margolin, S B
AU  - Margolin SB
LA  - eng
PT  - Journal Article
DEP - 20080211
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Culture Media)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Pyridones)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - D7NLD2JX7U (pirfenidone)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Survival/drug effects
MH  - Culture Media
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Etanercept
MH  - Humans
MH  - Immunoglobulin G/*pharmacology
MH  - Immunohistochemistry
MH  - Infliximab
MH  - Lipopolysaccharides/pharmacology
MH  - Pyridones/*pharmacology
MH  - Receptors, Tumor Necrosis Factor
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/biosynthesis
EDAT- 2008/04/05 09:00
MHDA- 2008/07/23 09:00
CRDT- 2008/04/05 09:00
PHST- 2007/10/31 00:00 [received]
PHST- 2008/01/14 00:00 [revised]
PHST- 2008/01/14 00:00 [accepted]
PHST- 2008/04/05 09:00 [pubmed]
PHST- 2008/07/23 09:00 [medline]
PHST- 2008/04/05 09:00 [entrez]
AID - S1567-5769(08)00015-5 [pii]
AID - 10.1016/j.intimp.2008.01.013 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2008 May;8(5):679-87. doi: 10.1016/j.intimp.2008.01.013. 
      Epub 2008 Feb 11.